Company intelligence / Profile preview
Pharming Group
- Ownership
- Public · PHAR
- Employees
- ~415
- Development stage
- Other
Overview
Pharming Group is a global biopharmaceutical company commercializing two main products. RUCONEST® is an approved recombinant human C1 esterase inhibitor for acute hereditary angioedema, marketed in the US, EU, and other regions. Joenja® (leniolisib) is the first and only FDA-approved treatment for APDS, launched in the US in 2023 with ongoing expansion into additional markets and pediatric indications. The company continues to expand its pipeline into related rare diseases and primary immunodeficiencies.
- Therapeutic areas
- Immunology
- Modalities
- Recombinant proteinSmall moleculeBiologicGene therapy
- Industry
- Biotech
Drug pipeline
5 assets4 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $870.6M
- Total revenue
- $376.1M
- Enterprise value
- $795.5M
Beyond the preview
Go deeper on Pharming Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pharming Group.